INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death [Yahoo! Finance]
Sarepta Therapeutics Provides Update on ELEVIDYS
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death [Yahoo! Finance]
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) had its price target lowered by analysts at Needham & Company LLC from $202.00 to $183.00. They now have a "buy" rating on the stock.